Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: jef saunders who wrote (13189)	12/11/2003 3:29:48 PM
From: padco	Read Replies (1) \| Respond to of 14101

jef - I'm thinking the same way. Perhaps we're being too pessimistic though. This company (and thousands more like it) has always tried to buy time while waiting for some big approval event to solve their financial problems. I think we're seeing it again with the focus on Pennsaid. Obviously, Rebecca and company have made a decision to sacrifice WF10 temporarily in the interest of solvency and hopefully unnecessary dilution of the share base. They are not prepared to shop out WF10 until the ph III results are in. The good news is that Dimethaid has broadened out its management team, and has brought on board some very good people. Check out Colin Campbell and Mini Brennan here... dimethaid.com Those who follow the patents and WF10 research will know of Dr. Michael McGrath. I've been disturbed to see little mention of him at DMX, but according to Rennie Ho, he still consults with the company. So despite the disappiontments, it looks like there is a business plan in place and that qualified people are being hired to advise and carry it out. Now if that big regulatory event were to come along....